News

First FDA approval without trials
Enlarge image

Clinical TrialsUK

First FDA approval without trials

18.12.2012 - GSK’s monoclonal antibody against anthrax is the first to get FDA approval without having been tested for efficacy in humans.

This antibody is a very special one: fast track designation, priority review, orphan drug designation – and the first monoclonal antibody approved under the FDA’s Animal Efficacy Rule: On 14 December, the U.S. Food and Drug Administration (FDA) approved GlaxoSmithKline’s (GSK) raxibacumab injections as a treatment against inhalational anthrax. „In addition to antibiotics, raxibacumab will be a useful treatment to have available should an anthrax bioterrorism event occur,“ said the FDA official Edward Cox. The decision comes as no surprise, as GSK announced that the FDA’s Anti-Infective Drugs Advisory Committee voted 16 to 1 in support of the clinical benefit of raxibacumab – with one abstention on 2 November. The antibody was discovered in a joint venture between Cambridge Antibody Technology and Human Genome Sciences with Cambridge Antibody Technology discovering the antibody to Human Genome Sciences' target. In July 2012 HGS was purchased by GSK.

Inhalational anthrax is a form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis. Raxibacumab neutralizes toxins produced by the bacterium that can cause massive and irreversible tissue injury and death. Raxibacumab has additionally been approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate. Its efficacy has been shown so far in rabbits and monkeys. „Sixty-four percent of animals in the monkey study and 44 percent of animals in one rabbit study receiving the 40 milligrams per kilogram dose of raxibacumab survived exposure to anthrax, compared with none in the placebo groups,“ said GSK in a press release. Trials in humans are not possible due the nature of the disease: Inhalational anthrax is as rare as it is lethal. However, at least the safety of raxibacumab could be demonstrated in 326 healthy human volunteers.

© eurobiotechnews.eu/ml

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

M&AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.

M&ASwitzerland

04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.

M&AFranceGermany

03.07.2014 Nicox S.A. is stretching beyond the European market: The French eye health specialist is set to acquire Aciex Therapeutics Inc., a US-based pharma company with several ophthalmic therapeutics nearing market maturity.

FinanceBelgium

01.07.2014 Belgian antibody specialist Ablynx has raised €41.7m through a private placement of new shares and plans on boosting their range of nanobodies in development.

BioeconomyBelgiumUK

30.06.2014 Building on a £1.2m financing round, Celtic Renewables partners with a Belgian pilot plant to bring its bio-fuel made from whisky production residue to an industrial scale.

ConventionEUUK

25.06.2014 Sun, celebrities and a scandal - the world’s largest biotech convention is getting off to an explosive start in San Diego, California.

InvestmentGermanyNetherlands

24.06.2014 Bayer Healthcare is getting back into gene therapy with a US$252m deal aimed at the development of a haemophilia A treatment.

InvestmentNetherlands

20.06.2014 Tomtom founder Pieter Geelen invests in Dutch biotech Ocello, the company behind a 3D mapping technology used for predicting drug behaviour in patients.

Events

All Events

Partner-Events

Vilnius (LT)

Life Sciences Baltics

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ADDEX (CH)4.29 CHF18.51%
  • COSMO PHARMACEUTICALS (CH)179.10 CHF7.76%
  • NEUROVIVE PHARMACEUTICAL AB (S)55.75 SEK6.19%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • BAVARIAN NORDIC (D)15.82 EUR-8.02%

TOP

  • SANTHERA (CH)72.80 CHF137.5%
  • CELLECTIS (F)13.63 EUR103.4%
  • ADDEX (CH)4.29 CHF92.4%

FLOP

  • THROMBOGENICS (B)8.92 EUR-50.4%
  • MERCK KGAA (D)64.16 EUR-50.1%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)72.80 CHF3576.8%
  • GW PHARMACEUTICALS (UK)444.50 GBP828.4%
  • IXICO (UK)55.50 GBP320.5%

FLOP

  • EVOCUTIS (UK)0.21 GBP-93.3%
  • CYTOS (CH)0.25 CHF-92.8%
  • THROMBOGENICS (B)8.92 EUR-72.4%

No liability assumed, Date: 09.07.2014